Treatment of Myotonia - Lamotrigine versus Namuscla

Rigshospitalet, department of Neurology0 个研究点目标入组 32 人开始时间: 2021年11月30日最近更新: 2022年2月1日

试验速览

暂无简介。

•1.Capable adult women and men (age = 18 years).
•2.Diagnosed with Myotonia Congenita (Becker and Thomsen type), Paramyotonia Congenita, or Hyperkalemic periodic paralysis.
•3.Myotonia under treatment or which significantly limits the daily activities (MBS> 2).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2

•1.Allergy to lamotrigine, mexiletine, or the inactive ingredients in trial medication.
•2.Disease, which is affected by trial medication such as heart disease (ischemia and arrhythmia), epilepsy, and significant renal or hepatic failure.
•3.Treatment that, in the opinion of the project manager, can affect the study result - medication with significant interactions with trial medication.
•4.In case of smoking, start or cessation during the study.
•5.Pregnant or breastfeeding during the study period. Fertile women with a positive pregnancy test at the time of entry into the trial, or who do not use safe contraception during the project period. The following contraceptives are considered safe: IUDs or hormonal contraceptives (birth control pills, implants, transdermal patches, vaginal ring or prolonged-release injections).

发起方

Rigshospitalet, department of Neurology